Demodex blepharitis presents with a wide variety of symptoms, which can range in severity from mild to more severe. The classic symptoms include itching along the lash and eyelid margins, diffuse eye discomfort, and fluctuating vision. Secondary meibomian gland dysfunction can further complicate the condition. Patients may also develop internal or external hordeola (styes), which can lead to chalazia, which are eyelid bumps caused by hardened oil deposits in the glands.
The primary issue with Demodex blepharitis is the overpopulation of mites in the hair follicles on the lashes, creating collarettes or scurf around the lash base. The mites can obstruct meibomian glands, causing symptoms similar to dry eye. To diagnose Demodex blepharitis, the clinician should observe the lid margin through a slit lamp at high magnification to look for fine collarettes at the base of the lashes.
Treating Demodex blepharitis has historically been challenging, with recommended treatments like hypochlorous spray, lid hygiene, warm compresses, and tea tree oil wipes providing limited relief. However, the introduction of lotilaner 0.25% ophthalmic solution offers an effective treatment option that alleviates symptoms and improves patient outcomes.
The prevalence of Demodex blepharitis was evaluated in the Tratler study, which revealed that approximately 57% to 58% of patients visiting eye care clinics have Demodex blepharitis, which is higher than previously thought. The high prevalence of Demodex blepharitis necessitates a change in clinical behavior to identify and treat affected patients.
This summary was AI-generated and reviewed by an AJMC editor.
For other articles and videos in this AJMC® Perspectives publication, please visit “Updates in the Management of Demodex Blepharitis”
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More